Methyclothiazide

Summary

Methyclothiazide (CHEMBL1577) is an approved small molecule (ATC C03AA08); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C03AA08
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 360.2 Da · C9H11Cl2N3O4S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1577
Name	Methyclothiazide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4121
ATC	C03AA08
Molecular formula	C9H11Cl2N3O4S2
Molecular weight	360.2
InChIKey	CESYKOGBSMNBPD-UHFFFAOYSA-N

SMILES: CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CCl

IUPAC name: 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1lambda6,2,4-benzothiadiazine-7-sulfonamide

Also known as: Aquatensen, Enduron, Methyclothiazide, Methyclothiazide component of enduronyl, Methyclothiazide component of eutron, Meticlotiazida, NSC-110431, METHYCLOTHIAZIDE, SID92764517, SID50112700, methyclothiazide, SID144206003

Patent coverage: 2,269 distinct patent families (7,322 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 7,284 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Muscarinic acetylcholine receptor M1, Alpha-1A adrenergic receptor.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00208442	PHASE4	COMPLETED	A Randomised Single Centre Study to Compare the Long-term Wear Characteristics of Marathon™ and Enduron™ Polyethylene Cup Liners in Primary Total Hip Replacement

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).